Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Treatment
Paclitaxel containing less Cremophor EL as first-line therapy for breast cancer
April 28th, 2005
Researchers proposed a novel formulation of paclitaxel containing less Cremophor EL as a first-line therapy for patients with advanced breast cancer. According to recent research from Taiwan, "Paclitaxel (Taxol) is formulated in 50% Cremophor EL (CrEL)/absolute ethanol for clinical use. In order to reduce vehicle-related side effects, Genetaxyl was developed to have paclitaxel formulated in a solution containing lesser amounts of CrEL and ethanol plus 2 other solvents. The purpose of the study was to evaluate the efficacy and safety of Genetaxyl as first-line therapy to treat breast cancer patients." "Patients with newly diagnosed stage III (n=8) or...
Source: Women's Health Weekly (2005-04-28)
|
